Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The 'KRAS Mutant Cancer - Pipeline Insight, 2024' drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive insights of present clinical development scenario and growth prospects across the KRAS Mutant Cancer market.

都柏林，2024年5月30日（环球通讯社）--“KRAS突变癌症-管道洞察，2024”药物管道已被添加到ResearchAndMarkets.com的产品中。本报告对KRAS突变癌症市场目前的临床发展情景和增长前景进行了全面的了解。

A detailed picture of the KRAS Mutant Cancer pipeline landscape is provided, which includes the disease overview and KRAS Mutant Cancer treatment guidelines. The assessment part of the report embraces in-depth KRAS Mutant Cancer commercial assessment and clinical assessment of the KRAS Mutant Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.

提供了KRAS突变癌症管道景观的详细图片，其中包括疾病概述和KRAS突变癌症治疗指南。报告的评估部分包括从临床前开发阶段到上市阶段对KRAS突变癌症管道产品进行深入的KRAS突变癌症商业评估和临床评估。

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, KRAS Mutant Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.The report provides insights into: All of the companies that are developing therapies for the treatment of KRAS Mutant Cancer with aggregate therapies developed by each company for the same.Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the KRAS Mutant Cancer treatment.KRAS Mutant Cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), lic.

在报告中，提供了该药物的详细描述，包括药物的作用机制，临床研究，NDA批准（如果有的话）以及包括技术，KRAS突变癌症合作，许可，合并和收购，资金，名称和其他产品相关细节的产品开发活动。该报告提供了以下见解：所有正在开发治疗KRAS突变型癌症的疗法的公司，每家公司都为此开发了综合疗法。对于KRAS突变型癌症治疗，不同的治疗候选物分为早期，中期和晚期。KRAS突变癌症的关键参与者参与了针对性治疗药物的开发，并分别参与了活跃和不活跃（休眠或停止）的项目。正在开发的药物基于开发阶段，给药途径，靶受体，单一疗法或联合疗法，不同的作用机制和分子类型。详细分析合作（公司-公司合作和公司-学术界合作），lic。